Restructuring Activities

3 Months Ended

Mar. 31, 2012

Restructuring and Related Activities [Abstract]

In April 2010, Caire Inc., a wholly-owned subsidiary of the Company, announced its plan to close its liquid oxygen therapy manufacturing facility in Plainfield, Indiana and relocate the manufacturing and customer service operations to a facility close to existing BioMedical operations in Canton, Georgia. The Plainfield facility was acquired as part of the 2009 acquisition of the liquid oxygen therapy business of Covidien plc. The closure was substantially completed in the second quarter of 2011. The total cost of the restructuring was approximately $7,300 which includes asset impairment charges. The cost includes cash expenditures for employee retention and separation benefits, as well as lease exit costs and loss on disposal of remaining assets.

The Company recorded $26 for the three months ended March 31, 2012 in restructuring costs for employee separation benefits related to the integration of SeQual Technologies Inc., which was acquired on December 28, 2010. These charges were recorded in selling, general and administrative expenses for the three months ended March 31, 2012. The Company recorded $199 for the three months ended March 31, 2011 related to the closure of the Plainfield, Indiana BioMedical facility. The Company also recorded $902 for the three months ended March 31, 2011 in restructuring costs for employee separation benefits related to the integration of SeQual Technologies Inc. These charges were recorded in cost of sales ($11 for the three months ended March 31, 2011) and selling, general and administrative expenses ($1,090 for the three months ended March 31, 2011).

The following tables summarize the Company’s restructuring activities for the three months ended March 31, 2012 and 2011:



	Three Months Ended March 31, 2012
	Energy & Chemicals		Distribution & Storage			BioMedical			Corporate		Total
Balance as of January 1, 2012	$	—	$	115		$	998		$	—	$	1,113
Restructuring charges	—		—			26			—		26
Cash payments and other	—		(73		)	(517		)	—		(590		)
Balance as of March 31, 2012	$	—	$	42		$	507		$	—	$	549



	Three Months Ended March 31, 2011
	Energy & Chemicals			Distribution & Storage			BioMedical			Corporate		Total
Balance as of January 1, 2011	$	103		$	387		$	2,088		$	—	$	2,578
Restructuring charges	—			(1		)	1,102			—		1,101
Cash payments and other	(39		)	(128		)	(790		)	—		(957		)
Balance as of March 31, 2011	$	64		$	258		$	2,400		$	—	$	2,722

- Definition

The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.

+ References+ Details